When patients were stratified according to their IGF1 × ULN, patients with full disease control did not show a significant difference in OSAS risk, daily sleepiness, and sleep disorders (59, 19.2, and 63.5%, respectively) compared to patients with partial disease control (65.6, 21.9, and 59.4%, respectively) and those with uncontrolled disease (54.3, 17.1, and 51.4%, respectively). The gene discussed is IGF1; the disease is sleep disorder.